From club drug to orphan drug: Sodium oxybate (Xyrem) for the treatment of cataplexy

Pharmacotherapy

Volumn 23, Issue 9 I, 2003, Pages 1205-1209

  Fuller, David E ^a   Hornfeldt, Carl S ^a  

^a JAZZ PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; ORPHAN DRUG; OXYBATE SODIUM; PLACEBO;

CATAPLEXY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; HUMAN; LAW; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NARCOLEPSY; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNITED STATES;

ADMINISTRATION, ORAL; CATAPLEXY; DRUG APPROVAL; HUMANS; ORPHAN DRUG PRODUCTION; PRODUCT SURVEILLANCE, POSTMARKETING; RISK MANAGEMENT; SODIUM OXYBATE; STREET DRUGS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0141568221     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.10.1205.32756     Document Type: Review

References (34)

1. Bowles TM, Sommi RW, Amiri M. Successful management of prolonged γ-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001;21:254-7.
2. Teter CJ, Guthrie SK. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001;21:1486-513.
3. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: Clinical features, new pathological insights, and future perspectives. J Clin Neurophysiol 2001;18:78-105.
4. Krahn LE, Black JL, Silber MH. Narcolepsy: new understanding of irresistible sleep. Mayo Clin Proc 2001;76:185-94.
5. Choo KL, Guilleminault C. Narcolepsy and idiopathic hypersomnolence. Clin Chest Med 1998;19:169-81.
6. Bassetti C, Aldrich MS. Narcolepsy Neurol Clin 1996;14:545-71.
7. Dauvilliers Y, Bazin M, Ondzé B, et al. Severity of narcolepsy among French of different ethnic origins (South of France and Martinique). Sleep 2002;25:50-5.
8. Anic-Labat S, Guilleminault C, Kraemer HC, et al. Validation of a cataplexy questionnaire in 983 sleep-disorder patients. Sleep 1999;22:77-87.
9. Honda Y. Clinical features of narcolepsy: Japanese experience. In: Honda Y, Juji T, eds. HLA in narcolepsy. New York: Springer-Verlag, 1988:24-57.
10. Ohayon MM, Priest RG, Zulley J, et al. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002;58:1826-33.
11. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000;27:469-74.
12. Sutcliffe JG, de Lecea L. The hypocretins: setting the arousal threshold. Nat Rev Neurosci 2002;3:339-49.
13. Siegel JM. Narcolepsy: a key role for hypocretins (orexins). Cell 1999;98:409-12.
14. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancer 2000;355:39-40.
15. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991-7.
16. Hublin C. Narcolepsy: current drug treatment options. CNS Drugs 1996;5:426-36.
17. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol 1964;3:433-52.
18. Bessman SP, Fishbein WN. γ-Hydroxybutyrate: a new metabolite in brain [abstr]. FASEB J 1963;22:334.
19. Maitre M. The γ-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol 1997;51:337-61.
20. Food and Drug Administration. γ-Hydroxybutyric acid [press release]. Rockville, MD: Food and Drug Administration, November 8, 1990.
21. Centers for Disease Control. Multistate outbreak of poisonings associated with illicit use of γ-hydroxy butyrate. JAMA 1991;256:447-8.
22. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of γ-hydroxybutyric acid overdose. Ann Emerg Med 1998;31:723-8.
23. El Sohly MA, Salamone SJ. Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 1999;23:141-6.
24. Craig K, Gomez HF, McManus JL, Bania TC. Severe γ-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000:18:65-70.
25. Anonymous. Schedules of controlled substances: addition of y-hydroxybutyric acid to schedule I. Federal Register 2000;65(49):13235-8.
26. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal γ-hydroxybutyrate. Can J Neurol Sci 1979;6:1-6.
27. Scharf M, Brown D, Woods M, Brown L, Hirschowitz J. The effects and effectiveness of γ-hydroxybutyrate in patients with narcolepsy J Clin Psych 1985;46:222-5.
28. Bédard MA, Montplaisir J, Godbout R, Lapierre O. Nocturnal γ-hydroxybutyrate: effect on periodis leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol 1989;12:29-36.
29. Scrima L, Hartman PG, Johnson FH, Thomas EE, Hiller FC. The effects of γ-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990;13:479-90.
30. Lammers GJ, Arends J, Declerck AC, et al. γ-hydroxybutyrate and narcolepsy: a double-blind placebo-controlled study Sleep 1993;6:216-20.
31. U. S. Xyrem Multicenter Study Group. A randomized, double-blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25:42-9.
32. Orphan Medical, Inc. Xyrem physician's monograph. Orphan Medical, Inc., Minnetonka, MN; 2002.
33. U. S. Xyrem Multicenter Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol 2003;41:131-5.
34. U. S. Xyrem Multicenter Study Group. A 12-month, open-label, multi-center extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003;26:31-5.